Literature DB >> 16614977

Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis.

D Rost1, G Rudolph, P Kloeters-Plachky, A Stiehl.   

Abstract

In primary sclerosing cholangitis (PSC), biliary enrichment of ursodeoxycholic acid (UDCA) may represent the decisive factor for its presumable beneficial effect. Up to now it is not clear how colitis and colectomy with ileo-anal pouch affect the biliary enrichment of UDCA and the biliary bile acid composition. We determined the biliary bile acid composition in 63 patients with PSC including 7 patients with ileo-anal pouch, 31 patients with colitis, and 25 patients without colitis. No differences existed between patients with and those without colitis. In patients with colectomy and pouch at a UDCA dose of 17.7 +/- 1.6 mg/kg (n = 7), biliary UDCA represented 46.4 +/- 6.7% (mean +/- SD) of total bile acids. An increase in the dose in six pouch patients from 12.5 +/- 0.9 to 22.3 +/- 1.6 mg/kg led to a slight increase in biliary enrichment of UDCA, from 39.8 +/- 8.1 to 49.4 +/- 10.7%. In five of seven patients with ileo-anal pouch, biliary UDCA enrichment was within the normal range, and in two of seven it was permanently or intermittently abnormally low. During UDCA treatment, in pouch patients the biliary content of deoxycholic acid and lithocholic acid was reduced, whereas all other bile acids were unchanged. In a minority of patients with ileo-anal pouch, biliary enrichment of UDCA may be markedly reduced, whereas patients with colitis have a biliary UDCA enrichment not different from that of patient without colitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16614977     DOI: 10.1007/s10620-006-3180-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes.

Authors:  P R Galle; L Theilmann; R Raedsch; G Otto; A Stiehl
Journal:  Hepatology       Date:  1990-09       Impact factor: 17.425

2.  Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.

Authors:  C Colombo; K D Setchell; M Podda; A Crosignani; A Roda; L Curcio; M Ronchi; A Giunta
Journal:  J Pediatr       Date:  1990-09       Impact factor: 4.406

3.  Ileal excretion of bile acids: comparison with biliary bile composition and effect of ursodeoxycholic acid treatment.

Authors:  A Stiehl; R Raedsch; G Rudolph
Journal:  Gastroenterology       Date:  1988-05       Impact factor: 22.682

4.  Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes.

Authors:  C Benz; S Angermüller; U Töx; P Klöters-Plachky; H D Riedel; P Sauer; W Stremmel; A Stiehl
Journal:  J Hepatol       Date:  1998-01       Impact factor: 25.083

5.  Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.

Authors:  Adolf Stiehl; Gerda Rudolph; Petra Klöters-Plachky; Peter Sauer; Siegfried Walker
Journal:  J Hepatol       Date:  2002-02       Impact factor: 25.083

6.  Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation.

Authors:  C M Rodrigues; X Ma; C Linehan-Stieers; G Fan; B T Kren; C J Steer
Journal:  Cell Death Differ       Date:  1999-09       Impact factor: 15.828

7.  Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria.

Authors:  T Fedorowski; G Salen; G S Tint; E Mosbach
Journal:  Gastroenterology       Date:  1979-11       Impact factor: 22.682

8.  Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids.

Authors:  A Stiehl; R Raedsch; G Rudolph
Journal:  Gastroenterology       Date:  1990-02       Impact factor: 22.682

9.  Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage.

Authors:  S Walker; G Rudolph; R Raedsch; A Stiehl
Journal:  Gastroenterology       Date:  1992-03       Impact factor: 22.682

10.  Tauroursodeoxycholate prevents taurocholate induced cholestasis.

Authors:  K Kitani; S Kanai
Journal:  Life Sci       Date:  1982-02-07       Impact factor: 5.037

View more
  2 in total

1.  Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.

Authors:  Emmanouil Sinakos; Hanns-Ulrich Marschall; Kris V Kowdley; Alex Befeler; Jill Keach; Keith Lindor
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

2.  Treatment of primary sclerosing cholangitis.

Authors:  Daniel Rost; Hasan Kulaksiz; Adolf Stiehl
Journal:  Curr Treat Options Gastroenterol       Date:  2007-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.